Wednesday, July 8, 2026

pharma · Chronic Spontaneous Urticaria (CSU) · Asthma · SPRY

Ars Pharmaceuticals Irl

Ars Pharmaceuticals Irl is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker SPRY. Primary therapeutic focus areas include Chronic Spontaneous Urticaria (CSU), Asthma, Urticaria, Upper

San Diego, USA HQ
187 Employees
Public company Type
SPRY · NYSE Ticker
Company details
Status
Public
HQ
San Diego, USA
Employees
187
Programs
8
Drugs
7
Patents
0
Clinical program

ARS-1 with URTI

Phase 1 · small molecule · Upper Respiratory Tract Infection

ARS-1 with URTI for Upper Respiratory Tract Infection is a Phase 1 program (small_molecule) at Ars Pharmaceuticals Irl Limited with 1 ClinicalTrials.gov record(s).

Internal code EPI 014

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Ars Pharmaceuticals Irl Limited
Phase
Phase 1
Modality
small_molecule
Indication
Upper Respiratory Tract Infection
Status
completed
Trials
1

Clinical trials